Clinical Trial Update: Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for multiple myeloma after allogeneic transplant was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ID-Specific Donor Vaccinated Lymphocyte Infusion

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2018-06-01